hepatic encephalopathy

**Background**: After 5 years since the registration of rifaximin-$\alpha$ as a secondary prophylaxis for overt hepatic encephalopathy (HE) in the Netherlands, we aimed to evaluate the use of hospital resources and safety of rifaximin-$\alpha$ …